{"id":545332,"date":"2021-05-28T19:36:01","date_gmt":"2021-05-28T19:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545332"},"modified":"2021-05-28T19:36:01","modified_gmt":"2021-05-28T19:36:01","slug":"systemic-lupus-erythematosus-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/systemic-lupus-erythematosus-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_545332.html","title":{"rendered":"Systemic lupus erythematosus Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Systemic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cSystemic lupus erythematosus \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Systemic lupus erythematosus, historical and forecasted epidemiology as well as the Systemic lupus erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Systemic lupus erythematosus -Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s “Systemic lupus erythematosus – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Systemic lupus erythematosus, historical and forecasted epidemiology as well as the  Systemic lupus erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. Among the EU5 countries, the UK had the highest diagnosed prevalent population of SLE with 62,852 cases, followed by Italy in 2017. On the other hand, Spain had the lowest prevalent population.<\/li>\n
  2. Females are more prone to SLE than males among all countries. In 2017, there were 233,735 prevalent cases of SLE in females and 25,740 prevalent cases in males in the United States as per DelveInsight’s analysts assessments.<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.The Systemic lupus erythematosus market report covers a descriptive overview and comprehensive insight of the Systemic lupus erythematosus epidemiology and Systemic lupus erythematosus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.The Systemic lupus erythematosus market report provides insights on the current and emerging therapies.<\/p>\n

    3.Systemic lupus erythematosus market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4.The Systemic lupus erythematosus market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Systemic lupus erythematosus market.<\/p>\n

    Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/systemic-lupus-erythematosus-market<\/a>
    <\/a><\/strong><\/p>\n

    Systemic lupus erythematosus: Overview<\/strong><\/p>\n

    Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder that affects multiple organ systems- the skin, kidneys, lungs, blood and, in the most severe cases, the brain. The therapeutic goals are individualized with the intention of achieving remission, preventing further organ damage, and improving the patient’s quality of life (QoL).<\/p>\n

    The key players involved in the Systemic lupus erythematosus market<\/a>:<\/strong><\/p>\n

      \n
    1. AstraZeneca<\/li>\n
    2. ImmuPharma<\/li>\n
    3. Eli Lilly<\/li>\n
    4. Janssen Pharmaceutica<\/li>\n
    5. Merck KGaA<\/li>\n
    6. ILTOO Pharma<\/li>\n
    7. Biogen<\/li>\n
    8. Celgene<\/li>\n
    9. UCB Pharma\/Biogen<\/li>\n
    10. Neovacs<\/li>\n
    11. Idorsia Pharmaceuticals<\/li>\n
    12. Kezar Life Sciences<\/li>\n
    13. Bristol-Myers Squibb<\/li>\n
    14. Xencor<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Systemic lupus erythematosus treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. Anifrolumab<\/li>\n
      2. Lupuzor<\/li>\n
      3. Baricitinib <\/li>\n
      4. Stelara<\/li>\n
      5. Atacicept<\/li>\n
      6. ILT-101<\/li>\n
      7. BIIB059 <\/li>\n
      8. CC-220<\/li>\n
      9. Dapirolizumab pegol <\/li>\n
      10. IFNα Kinoid<\/li>\n
      11. Cenerimod<\/li>\n
      12. KZR-616 <\/li>\n
      13. Lulizumab pegol<\/li>\n
      14. XmAb5871<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/systemic-lupus-erythematosus-market<\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Systemic lupus erythematosus Patient Share (%) Overview at a Glance<\/p>\n

        5. Systemic lupus erythematosus Market Overview at a Glance<\/p>\n

        6. Systemic lupus erythematosus Disease Background and Overview<\/p>\n

        7. Systemic lupus erythematosus Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Systemic lupus erythematosus <\/p>\n

        9. Systemic lupus erythematosus Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Systemic lupus erythematosus Emerging Therapies<\/p>\n

        12. Systemic lupus erythematosus Market Outlook<\/p>\n

        13. Country-Wise Systemic lupus erythematosus Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Systemic lupus erythematosus Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Systemic lupus erythematosus- Pipeline Insights, 2021<\/strong><\/p>\n

        “Systemic lupus erythematosus- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Systemic lupus erythematosus market. A detailed picture of the Systemic lupus erythematosus pipeline landscape is provided, which includes the disease overview and Systemic lupus erythematosus treatment guidelines.<\/p>\n

        Systemic lupus erythematosus -Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Systemic lupus erythematosus- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Systemic lupus erythematosus{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cSystemic lupus erythematosus \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Systemic lupus erythematosus, historical and forecasted epidemiology as well as the Systemic lupus erythematosus market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-545332","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545332"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545332\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}